X @Investopedia

Novartis said Tuesday it is buying Tourmaline Bio for $1.4 billion in a deal that gives the Swiss pharma giant access to the biotech’s late-stage cardiovascular drug pacibekitug. https://t.co/gsJCq5diXd ...